• Work order contract executed with George Clinical International to support the RAC-010 Phase 1 trial of RC220 bisantrene
• Trial will provide human safety and pharmacokinetic data, determine the maximum tolerated combined dose of RC220 and doxorubicin, and yield initial clinical data on the cardioprotective, anticancer and m6A RNA activity of RC220
• George Clinical is a leading global CRO with extensive trial experience globally

Race Oncology Ltd has executed a $8,582,117 work order contract with the Contract Research Organisation (CRO), George Clinical International, to support the clinical development of RC220 bisantrene. The RAC-010 Phase 1 trial will be conducted across multiple sites in Australia, Hong Kong and South Korea, and will use ascending doses of RC220 to determine its safety, tolerability, pharmacokinetics, maximum tolerated combined dose (MTCD) in combination with doxorubicin, and the effects on a range of clinical biomarkers including m6A RNA. After interim analysis, the optimal dosage of RC220 in combination with doxorubicin will be assessed in additional patients for further safety, tolerability, and preliminary cardioprotective and anticancer efficacy signals. George Clinical is a leading global CRO with more than 20 years of operational and extensive trial experience globally, and an impressive track record of success conducting oncology trials at all phases. The Phase 1 trial will use a Bayesian design enabling greater trial flexibility and speed.